Aurobindo stock gains on generic Advair launch

Aurobindo Pharma (INE406A01037) gained after its subsidiary launched generic Advair Diskus in the US, a move that gave traders a fresh product-level catalyst on September 1, 2026. The share price was last quoted at Rs 1,690.80, down 1.53%, while market capitalisation stood at Rs 98,792 crore in a market note published the same day.

Launch adds a US inhalation step

The new product launch matters because it is the first commercial US launch from the inhalation pipeline and it gives the company a visible near-term revenue lever. A market note published on September 1, 2026 said the launch covered the 100/50 mcg and 250/50 mcg strengths, which helps frame the scale of the rollout.

That same-day market backdrop also showed a strong stock re-rating after the announcement, with one report saying the shares touched an intraday high of Rs 1,703 and later traded at Rs 1,682.90, up 2.29% from the previous close of Rs 1,645.30 on the NSE. For investors, the number that stands out is the gap between the launch narrative and the market reaction: the stock still sat close to its recent high zone even after the session cooled.

Latest reported numbers

The most recent reported quarter visible in the sources was Q1 FY26, when revenue came in at Rs 88,851 million and net profit at Rs 18,527 million. One broker note also placed Q1 FY26 revenue at Rs 91,504 million, showing that different reporting cutoffs and presentation layers can produce slightly different reads on the same period.

On a year-over-year basis, that Q1 FY26 revenue figure was up 3.0% and net profit was up 3.9% in the same broker material. The quarter also pointed to a stronger domestic read, with one segment figure rising 16.3% to Rs 20,000 million in the cited table.

What the trend says

The launch is not the whole story. It lands against a business that has already posted a fresh quarterly base in Q1 FY26 and a share price that is trading in a high zone, so the market is still rewarding execution rather than waiting for a single quarter to prove the case.

Analysts in one recent market note also kept a constructive stance, with a target of Rs 1,820 and a stop loss of Rs 1,665 on the stock. That puts the current tape inside a tighter technical range than the product headline alone suggests.

Advair Diskus

Advair Diskus is Aurobindo's newly launched inhalation product in the US, and the commercial detail matters because it marks the first monetized step from that pipeline in that market. The launch comes in two strengths, 100/50 mcg and 250/50 mcg, which gives the rollout a practical starting point rather than a symbolic one.

Stock level

Aurobindo Pharma shares were last quoted at Rs 1,690.80 on September 1, 2026. The same-day market note placed market capitalisation at Rs 98,792 crore, while another session read showed the stock closing at Rs 1,717 with a 4.36% change in one market summary.

Fact box

Company: Aurobindo Pharma Ltd.
ISIN: INE406A01037
Ticker: AUROPHARMA
Exchange: NSE
Price (as of September 1, 2026): Rs 1,690.80
Market cap: Rs 98,792 crore
Sector / Industry: Healthcare / Pharmaceuticals